ストックスクリーナーアプリを入手
10.50
9.26%
0.89
アフターアワーズ：
10.50
前日終値:
$9.61
開ける：
$9.75
24時間の取引高:
5.38M
Relative Volume:
1.28
時価総額：
$3.22B
収益：
-
当期純損益:
$-125.04M
株価収益率:
-12.80
EPS:
-0.82
ネットキャッシュフロー:
$-122.99M
1週間 パフォーマンス:
+7.03%
1か月 パフォーマンス:
+201.72%
6か月 パフォーマンス:
+503.45%
1年 パフォーマンス:
+444.04%
1日の値動き範囲:
$9.6334
$10.52
1週間の範囲:
$8.77
$10.67
52週間の値動き範囲:
$1.01
$10.67
Erasca Inc Stock (ERAS) Company Profile
ERAS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
10.50 | 2.94B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | Piper Sandler | Overweight |
| 2025-10-16 | 開始されました | Stifel | Buy |
| 2025-09-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2025-08-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | 開始されました | Raymond James | Outperform |
| 2024-11-18 | 開始されました | Jefferies | Buy |
| 2024-03-11 | 開始されました | CapitalOne | Overweight |
| 2024-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2023-03-30 | 開始されました | Mizuho | Buy |
| 2023-02-24 | 開始されました | Goldman | Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Erasca Inc (ERAS) 最新ニュース
Guggenheim raises Erasca stock price target to $12 on RAS inhibitor progress - Investing.com
Erasca stock price target raised to $15 from $11 at H.C. Wainwright - Investing.com
Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? - Benzinga
Morgan Stanley Raises Price Target on Erasca to $10 From $4, Keeps Equalweight Rating - marketscreener.com
Fundamentals Check: How does Erasca Inc perform in inflationary periods2025 Price Momentum & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Erasca completes $258.8 million public offering of common stock By Investing.com - Investing.com South Africa
Investor Mood: Should I average down on Erasca Inc stock2025 Major Catalysts & Stock Portfolio Risk Control - baoquankhu1.vn
Erasca completes $258.8 million public offering of common stock - Investing.com
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - manilatimes.net
Erasca stock hits 52-week high at 10.46 USD By Investing.com - Investing.com Nigeria
Erasca Announces Major Underwritten Public Equity Offering - TipRanks
Erasca, Inc. Announces Upsized Public Offering of Common Stock - TradingView
Erasca raises $225M to sharpen RAS oncology focus - BioWorld MedTech
Latham & Watkins Advises Erasca in Upsized US$225 Million Offering of Common Stock - Latham & Watkins LLP
Erasca prices $225M stock offering at $10 per share - MSN
A trio of biotechs targets $500M+ offerings - Endpoints News
Erasca stock hits 52-week high at 10.46 USD - Investing.com
Top 2 Tech Stocks That Are Ticking Portfolio Bombs - Benzinga
ERAS Stock Surges 61% With A 6-day Winning Spree On HC Wainwright’s $11 Target - Trefis
Erasca Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Erasca, Inc. Announces Pricing of $225 Million Public Offering of Common Stock - Quiver Quantitative
Cancer drug developer Erasca raises $225M in stock sale - Stock Titan
Erasca (ERAS) soars 42% on bullish rating, PT upgrade - MSN
Top 2 Industrials Stocks That May Collapse In Q1 - Benzinga
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Erasca Stock Pre-Market (-8.3%): Proposed $150M Stock Offering - Trefis
Erasca plans to raise $150 million in public stock offering By Investing.com - Investing.com Nigeria
Erasca Announces $150 Million Public Offering; Stock Down - Nasdaq
Erasca Stock Pre-Market (-8.3%) : Announces $150M Public Stock Offering - Trefis
Erasca plans $150M public stock offering - MSN
Erasca reports preliminary year-end cash and securities of $341.8 million - Investing.com Nigeria
Erasca stock falls after announcing $150 million public offering - Investing.com
Erasca stock falls after announcing $150 million public offering By Investing.com - Investing.com South Africa
Erasca announces proposed public offering of $150 million of common stock - marketscreener.com
Erasca (ERAS) Stock Slides After The Bell: Here's Why - Benzinga
Erasca (ERAS) Announces $150M Public Offering to Fund Cancer Research - Intellectia AI
Erasca plans to raise $150 million in public stock offering - Investing.com
Erasca, Inc. Announces Proposed Public Offering of $150 Million in Common Stock - Quiver Quantitative
Erasca Announces Proposed Public Offering of $150 Million of Common Stock - The Manila Times
Cancer drug developer Erasca plans $150M stock sale to fund R&D - Stock Titan
Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade - Finviz
Erasca (ERAS) touches 3-year high as 4 analysts go bullish; gets 267% PT hike - MSN
Do Early ERAS-0015 Data Reframe Erasca’s (ERAS) Ambitions in RAS-Targeted Oncology? - simplywall.st
Erasca stock surges 42% in a week: Here's what you should know - MSN
Erasca price target raised to $2 from $1 at BofA - MSN
Erasca (ERAS) Valuation Comes Into Focus After Early ERAS-0015 Data At JP Morgan Healthcare Conference - simplywall.st
Erasca Inc (ERAS) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):